BIOGEN INC. Inventory Write-down
BIOGEN INC. (BIIB) reported Inventory Write-down of $4.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-04-29
- BIOGEN INC. inventory write-down for the quarter ending 2026-03-31 was $4.80M, a 34.25% decline year-over-year.
- BIOGEN INC. inventory write-down for the quarter ending 2025-12-31 was $15.30M, a 53.92% decline year-over-year.
- BIOGEN INC. inventory write-down for the quarter ending 2025-09-30 was -$400.00K, a 101.65% decline year-over-year.
- BIOGEN INC. inventory write-down for the quarter ending 2025-06-30 was $7.00M, a 58.58% decline year-over-year.
- BIOGEN INC. inventory write-down for fiscal 2025 was $29.20M, a 71.34% decline from fiscal 2024.
- BIOGEN INC. inventory write-down for fiscal 2024 was $101.90M, a 18.09% decline from fiscal 2023.
- BIOGEN INC. inventory write-down for fiscal 2023 was $124.40M, a 63.00% decline from fiscal 2022.
- BIOGEN INC. inventory write-down for fiscal 2022 was $336.20M, a 100.60% increase from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month | Inventory Write-down 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $4.80M 10-Q · filed 2026-04-29 | $20.10M derived: sum of 2 quarters · filed 2026-04-29 | $19.70M derived: sum of 3 quarters · filed 2026-04-29 | $26.70M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2025-12-31 | $15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $14.90M derived: sum of 2 quarters · filed 2026-02-06 | $21.90M derived: sum of 3 quarters · filed 2026-02-06 | $29.20M 10-K · filed 2026-02-06 | |
| 2025-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.60M derived: sum of 2 quarters · filed 2025-10-30 | $13.90M 10-Q · filed 2025-10-30 | $47.10M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2025-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $14.30M 10-Q · filed 2025-07-31 | $47.50M derived: sum of 3 quarters · filed 2026-04-29 | $71.80M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2025-03-31 | $7.30M 10-Q · filed 2026-04-29 | $40.50M derived: sum of 2 quarters · filed 2026-04-29 | $64.80M derived: sum of 3 quarters · filed 2026-04-29 | $81.70M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $33.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $57.50M derived: sum of 2 quarters · filed 2026-02-06 | $74.40M derived: sum of 3 quarters · filed 2026-02-06 | $101.90M 10-K · filed 2026-02-06 | |
| 2024-09-30 | $24.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $41.20M derived: sum of 2 quarters · filed 2025-10-30 | $68.70M 10-Q · filed 2025-10-30 | $131.00M derived: sum of 4 quarters · filed 2026-02-06 | |
| 2024-06-30 | $16.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $44.40M 10-Q · filed 2025-07-31 | $106.70M derived: sum of 3 quarters · filed 2026-02-06 | $132.00M derived: sum of 4 quarters · filed 2026-02-06 | |
| 2024-03-31 | $27.50M 10-Q · filed 2025-05-01 | $89.80M derived: sum of 2 quarters · filed 2026-02-06 | $115.10M derived: sum of 3 quarters · filed 2026-02-06 | $134.50M derived: sum of 4 quarters · filed 2026-02-06 | |
| 2023-12-31 | $62.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $87.60M derived: sum of 2 quarters · filed 2026-02-06 | $107.00M derived: sum of 3 quarters · filed 2026-02-06 | $124.40M 10-K · filed 2026-02-06 | |
| 2023-09-30 | $25.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $44.70M derived: sum of 2 quarters · filed 2024-10-30 | $62.10M 10-Q · filed 2024-10-30 | $76.70M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $19.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $36.80M 10-Q · filed 2024-08-01 | $51.40M derived: sum of 3 quarters · filed 2025-02-12 | $67.40M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $17.40M 10-Q · filed 2024-04-24 | $32.00M derived: sum of 2 quarters · filed 2025-02-12 | $48.00M derived: sum of 3 quarters · filed 2025-02-12 | $72.10M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $14.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $30.60M derived: sum of 2 quarters · filed 2025-02-12 | $54.70M derived: sum of 3 quarters · filed 2025-02-12 | $336.20M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $16.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $40.10M derived: sum of 2 quarters · filed 2023-11-08 | $321.60M 10-Q · filed 2023-11-08 | $452.70M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-06-30 | $24.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $305.60M 10-Q · filed 2023-07-25 | $436.70M derived: sum of 3 quarters · filed 2024-02-14 | $464.90M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-03-31 | $281.50M 10-Q · filed 2023-04-25 | $412.60M derived: sum of 2 quarters · filed 2024-02-14 | $440.80M derived: sum of 3 quarters · filed 2024-02-14 | $437.20M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2021-12-31 | $131.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $159.30M derived: sum of 2 quarters · filed 2024-02-14 | $155.70M derived: sum of 3 quarters · filed 2024-02-14 | $167.60M 10-K · filed 2024-02-14 | |
| 2021-09-30 | $28.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $24.60M derived: sum of 2 quarters · filed 2022-10-25 | $36.50M 10-Q · filed 2022-10-25 | ||
| 2021-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $8.30M 10-Q · filed 2022-07-20 | |||
| 2021-03-31 | $11.90M 10-Q · filed 2022-05-03 | ||||
| 2020-12-31 | $26.60M 10-K · filed 2023-02-15 | ||||
| 2019-12-31 | $52.20M 10-K · filed 2022-02-03 | ||||
| 2018-12-31 | $41.90M 10-K · filed 2021-02-03 | ||||
| 2017-12-31 | $76.90M 10-K · filed 2020-02-06 | ||||
| 2016-12-31 | $48.20M 10-K · filed 2019-02-06 | ||||
| 2015-12-31 | $41.90M 10-K · filed 2018-02-01 | ||||
| 2014-12-31 | $50.60M 10-K · filed 2017-02-02 | ||||
| 2013-12-31 | $47.30M 10-K · filed 2016-02-03 | ||||
| 2012-12-31 | $24.80M 10-K · filed 2015-02-04 | $24.82M 10-K · filed 2013-02-05 | |||
| 2011-12-31 | $8.54M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $18.10M derived: sum of 2 quarters · filed 2014-02-06 | $24.23M derived: sum of 3 quarters · filed 2014-02-06 | $25.40M 10-K · filed 2014-02-06 | $25.45M 10-K · filed 2012-02-03 |
| 2011-09-30 | $9.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $15.69M derived: sum of 2 quarters · filed 2011-10-28 | $16.86M 10-Q · filed 2011-10-28 | $18.75M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-06-30 | $6.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $7.30M 10-Q · filed 2011-07-26 | $9.19M derived: sum of 3 quarters · filed 2013-02-05 | $13.45M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-03-31 | $1.17M 10-Q · filed 2011-04-21 | $3.06M derived: sum of 2 quarters · filed 2013-02-05 | $7.32M derived: sum of 3 quarters · filed 2013-02-05 | $10.69M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2010-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $6.15M derived: sum of 2 quarters · filed 2013-02-05 | $9.52M derived: sum of 3 quarters · filed 2013-02-05 | $11.81M 10-K · filed 2013-02-05 | |
| 2010-09-30 | $4.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $7.63M derived: sum of 2 quarters · filed 2011-10-28 | $9.92M 10-Q · filed 2011-10-28 | $13.41M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $5.65M 10-Q · filed 2011-07-26 | $9.15M derived: sum of 3 quarters · filed 2012-02-03 | $11.10M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-03-31 | $2.29M 10-Q · filed 2011-04-21 | $5.78M derived: sum of 2 quarters · filed 2012-02-03 | $7.74M derived: sum of 3 quarters · filed 2012-02-03 | $9.83M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2009-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $5.45M derived: sum of 2 quarters · filed 2012-02-03 | $7.54M derived: sum of 3 quarters · filed 2012-02-03 | $16.92M 10-K · filed 2012-02-03 | |
| 2009-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $4.04M derived: sum of 2 quarters · filed 2010-10-26 | $13.43M 10-Q · filed 2010-10-26 | $20.81M derived: sum of 4 quarters · filed 2011-02-04 | |
| 2009-06-30 | $2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $11.47M 10-Q · filed 2010-07-20 | $18.85M derived: sum of 3 quarters · filed 2011-02-04 | ||
| 2009-03-31 | $9.39M 10-Q · filed 2010-04-20 | $16.76M derived: sum of 2 quarters · filed 2011-02-04 | |||
| 2008-12-31 | $7.38M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $29.85M 10-K · filed 2011-02-04 | |||
| 2008-09-30 | $22.47M 10-Q · filed 2009-10-21 | ||||
| 2007-12-31 | $21.60M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |